394 related articles for article (PubMed ID: 33094669)
21. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
[TBL] [Abstract][Full Text] [Related]
22. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
23. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
[TBL] [Abstract][Full Text] [Related]
24. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
[TBL] [Abstract][Full Text] [Related]
25. Repurposed Tocilizumab in Patients with Severe COVID-19.
Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
[TBL] [Abstract][Full Text] [Related]
26. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
27. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
28. The role of IL-6 and IL-6 blockade in COVID-19.
Potere N; Batticciotto A; Vecchié A; Porreca E; Cappelli A; Abbate A; Dentali F; Bonaventura A
Expert Rev Clin Immunol; 2021 Jun; 17(6):601-618. PubMed ID: 33874829
[TBL] [Abstract][Full Text] [Related]
29. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
Geng J; Wang F; Huang Z; Chen X; Wang Y
Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
31. Focus shifts to antibody cocktails for COVID-19 cytokine storm.
Harrison C
Nat Biotechnol; 2020 Aug; 38(8):905-908. PubMed ID: 32760027
[No Abstract] [Full Text] [Related]
32. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.
Kelleni MT
Expert Rev Anti Infect Ther; 2022 Jan; 20(1):17-21. PubMed ID: 34088250
[TBL] [Abstract][Full Text] [Related]
33. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Crisafulli S; Isgrò V; La Corte L; Atzeni F; Trifirò G
BioDrugs; 2020 Aug; 34(4):415-422. PubMed ID: 32557214
[TBL] [Abstract][Full Text] [Related]
34. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R; Karami P; Heidary AH; Esmaeilzadeh A
Int Immunopharmacol; 2022 Apr; 105():108536. PubMed ID: 35074571
[TBL] [Abstract][Full Text] [Related]
35. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
Front Immunol; 2021; 12():675678. PubMed ID: 33995419
[TBL] [Abstract][Full Text] [Related]
36. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
[TBL] [Abstract][Full Text] [Related]
37. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
Solis-García Del Pozo J; Galindo MF; Nava E; Jordán J
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7475-7484. PubMed ID: 32706087
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Covid-19 cytokine storm by tocilizumab.
Boretti A; Banik B
J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
[TBL] [Abstract][Full Text] [Related]
39. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
Meira F; Albiach L; Carbonell C; Martín-Oterino JA; Martín-Ordiales M; Linares L; Macaya I; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Morata L; Puerta-Alcalde P; Rico V; Letona L; Cózar-Llistó A; Dueñas G; Solá M; Torres B; Rojas J; Moreno A; Moreno-García E; Torres M; Martínez JA; Soriano A; García F
Rev Esp Quimioter; 2021 Aug; 34(4):337-341. PubMed ID: 33982984
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
